|

Gemcitabine Clinical Trials

181 actively recruiting trials across 52 locations

Also known as: 2', 2'-difluoro 2'deoxycytidine, Aerosolized GCB, C9H11F2N3O4 - HCl, Control, Difluorodeoxycytidine, Difluorodeoxycytidine Hydrochloride, FF 10832, GCB, GEM, GEM, Gemzar, GEMZAR®, Gem, Gemcitabin-GRY, Gemcitabine Hydrochloride, Gemcitabine Hydrochloride for Injection, Gemcitabine arm, Gemcitabine hydrochloride, Gemzar, Gemzar®, Infugem, LY188011, Nab-Paclitaxel, aerosol gemcitabine, celecoxib, chemotherapy, dFdC, dFdCyd, gemcitabine hydrocholoride

Other76 trials

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Phase 2
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
Phase 2
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Phase 1/2
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Phase 2
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Phase 2
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
Phase 1
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Phase 3
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
Phase 2/3
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Phase 1/2
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Phase 2
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
N/A
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Phase 3
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Phase 2
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Phase 1/2
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Phase 3
AB122 Platform Study
Phase 1
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Phase 2
Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease
Phase 2
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
Phase 2
Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma
Phase 2
Chemoablation for Low-Grade Bladder Cancer
Phase 2
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Phase 2/3
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
N/A
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
Phase 2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Phase 2
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
Phase 3
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Phase 2
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Phase 2
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Phase 3
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Phase 2
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Phase 3
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
Phase 2
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
Phase 2
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Phase 1/2
Investigator-initiated Clinical Trial of MIKE-1
Phase 1/2
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Phase 2
Metastatic Nasopharyngeal Carcinoma
Phase 1
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Phase 2
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Phase 3
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Phase 2
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2
PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
Phase 2
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Phase 3
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Phase 2
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Phase 2
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3
Personalized Medicine for Advanced Biliary Cancer Patients
Phase 3
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Early 1
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Phase 2
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
Phase 2
Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
N/A
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Phase 3
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Phase 2
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Phase 3
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Phase 2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/2
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
Phase 2/3
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Phase 3
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
N/A
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Phase 2
Targeting ATR in Soft-tissue Sarcomas
Phase 2
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Phase 3
The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy
Phase 2
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Phase 2
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Phase 2
Using ctDNA to Determine Therapies for Lung Cancer
Phase 2

Birmingham, Alabama8 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Children's Hospital of Alabama

Phase 2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

University of Alabama at Birmingham

Phase 1/2
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

University of Alabama at Birmingham

Phase 1
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Research Site

Phase 2
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

University of Alabama at Birmingham Cancer Center

Phase 3

Duarte, California8 trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

City of Hope National Medical Center /ID# 273338

Phase 3
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

City of Hope Medical Center

Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

City of Hope Medical Center

Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

City of Hope

Phase 1
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

City of Hope Medical Center

Phase 1
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

New York, New York6 trials

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Ambulatory Care Center

Phase 1
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Phase 3
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Columbia University Irving Medical Center

Phase 2
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 1/2
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Columbia University Medical Center

Phase 2

Houston, Texas6 trials

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

MD Anderson Cancer Center

Phase 1
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

M D Anderson Cancer Center

Phase 2
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

MD Anderson Cancer Center

Phase 1/2
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M D Anderson Cancer Center

Phase 2
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

The University of Texas MD Anderson Cancer Center

Phase 1
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

M D Anderson Cancer Center

Phase 1/2

Gilbert, Arizona4 trials

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Banner Health- MD Anderson Cancer Center

Phase 1/2
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Local Institution - 0167

Phase 2/3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Banner MD Anderson Cancer Center

Phase 3

Phoenix, Arizona4 trials

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Local Institution - 0142

Phase 2/3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Mayo Clinic Scottsdale - PPDS

Phase 3
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

BCG Oncology

Phase 1/2
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Phoenix Children's Hospital

Phase 1

Baltimore, Maryland4 trials

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Local Institution - 0009

Phase 1/2
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Maryland Proton Treatment Center

Phase 1
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Sidney Kimmel Comprehensive Cancer Center

Phase 2
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

SKCCC Johns Hopkins

Phase 2

Mobile, Alabama3 trials

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

University of South Alabama Mitchell Cancer Institute

Phase 2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

USA Mitchell Cancer Institute-Clinical Trials ( Site 4126)

Phase 3

Little Rock, Arkansas3 trials

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

University of Arkansas for Medical Sciences

Phase 4
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Arkansas Urology

Phase 3

Columbus, Ohio3 trials

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Ohio State University Comprehensive Cancer Center

Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Ohio State University Comprehensive Cancer Center

Phase 2
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Ohio State University Comprehensive Cancer Center

Phase 1/2

Daphne, Alabama2 trials

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Research Site

Phase 3
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Anchorage, Alaska2 trials

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Alaska Oncology & Hematology, LLC

Phase 2
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Anchorage Associates in Radiation Medicine

Phase 3

Scottsdale, Arizona2 trials

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic in Arizona

Phase 2
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Site

Phase 3

Tucson, Arizona2 trials

ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

The University of Arizona Cancer Center - North Campus

Phase 1/2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Hot Springs, Arkansas2 trials

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0303

Phase 2/3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Genesis Cancer and Blood Institute (SCRI)

Phase 2/3

Bakersfield, California2 trials

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Comprehensive Blood and Cancer Center

Phase 1
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

AIS Cancer Center at San Joaquin Community Hospital

Phase 2

El Segundo, California2 trials

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

Chan Soon-Shiong Institute for Medicine

Phase 1/2
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Chan Soon-Shiong Institute for Medicine

Phase 2

Irvine, California2 trials

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 3
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Los Angeles, California2 trials

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Cedars-Sinai Medical Center

Phase 1/2
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

American Institute of Research

Phase 3

Santa Monica, California2 trials

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Sant P Chawla

Phase 2
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Sarcoma Oncology Center

Phase 2/3

Miami, Florida2 trials

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

University of Miami

Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

University of Miami

Phase 2

Atlanta, Georgia2 trials

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

Arthur M. Blank Children's Healthcare of Atlanta

Phase 1

Boston, Massachusetts2 trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Massachusetts General Hospital

Phase 1
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2

Philadelphia, Pennsylvania2 trials

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2

Chandler, Arizona1 trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Ironwood Cancer and Research Centers

Phase 1/2

Glendale, Arizona1 trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)

Phase 2/3

Fort Smith, Arkansas1 trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Mercy Hospital Fort Smith

Phase 3

Springdale, Arkansas1 trial

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Highlands Oncology Group

Phase 3

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Fullerton, California1 trial

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site

Phase 2/3

La Jolla, California1 trial

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

UC San Diego Moores Cancer Center

Phase 1

Loma Linda, California1 trial

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

VA Loma Linda Healthcare System

Phase 3

Orange, California1 trial

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Research Site

Phase 2

Sacramento, California1 trial

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 2

San Diego, California1 trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

University of California San Diego Moores Cancer Center

Phase 1

Aurora, Colorado1 trial

A Study of ZN-c3 in Patients With Ovarian Cancer

Site 0264

Phase 1

Lakewood, Colorado1 trial

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Colorado Clinical Research

Phase 3

Washington D.C., District of Columbia1 trial

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

MedStar Georgetown University Hospital

Phase 1/2

Gainesville, Florida1 trial

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

University of Florida

Phase 2

Jacksonville, Florida1 trial

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Mayo Clinic in Florida

Phase 1/2

Tampa, Florida1 trial

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Moffitt Cancer Center

Phase 2

Chicago, Illinois1 trial

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

University of Illinois Cancer Center

N/A

Indianapolis, Indiana1 trial

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Louisville, Kentucky1 trial

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

University of Louisville

Phase 1

Bethesda, Maryland1 trial

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

National Heart, Lung, and Blood Institute (NIH) (Data Collection Only)

Phase 2

Clarkston, Michigan1 trial

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Karmanos Cancer Institute at McLaren Clarkston

Phase 2

Basking Ridge, New Jersey1 trial

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities

Phase 2

East Setauket, New York1 trial

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

North Shore Hematology Oncology Associates

Phase 1

Chapel Hill, North Carolina1 trial

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Phase 1/2

Huntersville, North Carolina1 trial

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Carolina BioOncology Institute

Phase 1/2

Winston-Salem, North Carolina1 trial

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Dallas, Texas1 trial

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

University of Texas Southwestern Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.